Vandetanib
| Name | Vandetanib |
|---|---|
| Supplier | Cell Signaling Technology |
| Catalog | 12616 |
| Prices | $114.00 |
| Sizes | 5 mg |
| Formula | C22H24BrFN4O2 |
| Molecular Weight | 475.35 g/mol |
| Purity | >99% |
| Description | Vandetanib, also known as ZD6474, is a selective inhibitor of VEGFR and EGFR tyrosine kinases (1-5). Researchers have shown that vandetanib inhibits VEGFR-2, VEGFR-3, and EGFR in recombinant enzyme assays with IC 50 values of 40 nM, 108 nM, and 500 nM, respectively, and had selectivity over a variety of other tyrosine and serine/threonine kinases (2). Vandetanib inhibits VEGF and EGF stimulated proliferation of HUVE cells with an IC 50 of 60 nM and 170 nM, respectively (2), and effectively blocks VEGF and EGF induced autophosphorylation (3-5). Inhibition of RET by vandetanib has also been observed (6). |
| Supplier Page | Shop |
Product images
Western blot analysis of extracts from HUVE cells serum-starved overnight, untreated (-) or pre-treated with Vandetanib (5 µM, 2 hr; +) and treated with Human Vascular Endothelial Growth Factor-165 (hVEGF 165 ) #8065 (50 ng/ml, 5 min; +) as indicated, using Phospho-VEGF Receptor 2 (Tyr1175) (19A10) Rabbit mAb #2478 (upper) or VEGF Receptor 2 (55B11) Rabbit mAb #2479 (lower).
Chemical structure of vandetanib.